Management of immune thrombocytopenia: 2022 update of Korean experts recommendations
Blood Research
;
: 20-28, 2022.
Article
in English
| WPRIM
| ID: wpr-925647
ABSTRACT
Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
/
Practice guideline
/
Prognostic study
Language:
English
Journal:
Blood Research
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS